T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab Breast Cancer

Conclusion Tumor response rates were lower than in prior reports of trastuzumab-resistant, HER2-positive MBC, but one third of patients received therapy with T-DM1 for ≥ 6 months, which suggests a clinically relevant benefit in patients who received prior pertuzumab.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Chemotherapy Breast Cancer Source Type: research

Related Links:

Condition:   Invasive Breast Cancer Interventions:   Drug: Cemiplimab;   Drug: Paclitaxel;   Drug: Carboplatin (not mandatory);   Drug: Doxorubicin;   Drug: Cyclophosphamide Sponsor:   Medical College of Wisconsin Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: The IL-10 gene rs1800872 polymorphism was associated with BC susceptibility in this sample from the Mexican population. PMID: 31983108 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Current imaging methods that are used to spot tumors don’t provide much information about the rate of activity of the cells making up the diseased tissues. Breast cancer tumors, for example, are mostly classified into a few categories based on ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Materials Medicine Oncology Radiology Source Type: blogs
The objective was to compare post-operative complication rates among patients treated with partial mastectomy (PM), unilateral mastectomy (UM), and bilateral mastectomy (BM) after NAC.Study design398 patients with breast cancer who had NAC from 2008 to 2016 were identified from a prospectively maintained database. The primary outcome measure was 30-day post-operative morbidity.Results125 patients (31.4%) underwent PM, 107 patients (26.9%) UM, and 166 (41.7%) BM. There was no significant difference among the 3 groups with respect to histology (ductal: 96.0% PM, 88.8% UM, 92.6% BM, p = 0.161). Groups were similar with re...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
AbstractBackgroundGiven presumed differences in disease severity between young ( ≤ 45 years) and elderly (≥ 75 years) women with breast cancer, we sought to compare tumor histopathology, stage at presentation, patterns of care, and survival at the extremes of age.MethodsAdults with stages 0 –IV breast cancer in the National Cancer Database (2004–2015) were categorized by age (18–45 years, 46–74 years, ≥ 75 years) and compared. Kaplan–Meier curves were used to visualize unadjusted overall survival (OS). A Cox proportional-hazards mod...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Abstract BACKGROUND: The combination of bevacizumab and chemotherapy has greatly improved progression-free survival (PFS) and objective response rate (ORR) in HER2-negative metastatic breast cancer in many pivotal trials. However, risk-benefit balance related to bevacizumab addition could not be confirmed because of a lack of overall survival (OS) improvement. Therefore, we conducted a meta-analysis to evaluate multiple endpoints pertaining to bevacizumab use in metastatic breast cancer (MBC) treatment. METHODS: We searched PubMed and Cochrane Library databases and included seven studies in our meta-analysis ...
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
This study is conducted to further evaluate the efficacy and safety of CDK4/6 inh ibitors for HR+ /HER2− ABC, and explore the prefer population through subgroup analysis.MethodWe identified relevant  randomized controlled trials that compared CDK4/6 inhibitors plus ET to ET alone in HR+ /HER2− ABC. We calculated the hazard ratios (HRs) for PFS and OS, and risk ratios (RRs) for objective response rate (ORR), clinical benefit rate (CBR), adverse events (AEs). Statistical analysis was perfo rmed with the random-effects model.ResultEight trials and 4580 patients were included in thi...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S Abstract With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA)...
Source: Journal of Carcinogenesis - Category: Cancer & Oncology Tags: J Carcinog Source Type: research
Conditions:   Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   Sentinel Lymph Node Intervention:   Procedure: Omission of sentinel lymph node biopsy Sponsor:   The Netherlands Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: As neoadjuvant therapy, the Nab-PTX regimen has advantages over conventional taxane regimen in patients with HER2-negative breast cancer. With this regimen, a high pCR rate was achieved with a good safety profile.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | HER2 | Herceptin | Study | Toxicology | Yale